Breakthrough CAR T-Cell Therapy Puts Lupus Patients Into Long-Term Remission

A pioneering CAR T-cell therapy trial has put severe lupus patients in remission for the first time, according to the UK’s National Health Service (NHS), marking a potential breakthrough for a disease that has long defied effective treatment. The therapy, originally developed for blood cancers, was tested on five patients with treatment-resistant lupus at London’s Great Ormond Street Hospital and University College London Hospitals, with all five achieving remission within three months, the Guardian reported.

The results, published in a peer-reviewed study in The Lancet on June 14, 2026, show that the therapy—known as autologous anti-CD19 CAR T-cell treatment—targets overactive immune cells that drive lupus. Unlike standard immunosuppressants, which merely suppress symptoms, the therapy appears to reset the immune system, allowing patients to discontinue other medications. "This is the first time we’ve seen sustained remission in lupus patients using this approach," said Dr. Emma Thomas, lead researcher at UCL’s Institute of Immunity and Transplantation.

Why is this different from existing lupus treatments?
Lupus affects an estimated 5 million people worldwide, with about 10% of patients developing severe, treatment-resistant forms that leave them bedridden or dependent on daily steroids. Current therapies—including belimumab (Benlysta) and rituximab—only control symptoms in roughly 30% of severe cases, according to the Lupus Foundation of America. The CAR T-cell trial, by contrast, achieved remission in all five participants, with no serious side effects beyond temporary cytokine release syndrome, a known reaction to the therapy.

The therapy works by extracting a patient’s own T-cells, genetically modifying them to target CD19—a protein found on B-cells that drive lupus—and then reinfusing them. Early data suggest the effect lasts at least six months, though long-term durability remains unproven. "We’re not claiming a cure yet, but for patients who’ve exhausted every other option, this could be transformative," said Professor Sir Peter Johnson, NHS England’s medical director, in a statement to Upday News.

How does the UK trial compare to earlier research?
The approach builds on decades of CAR T-cell research for cancers like leukemia, where the therapy has achieved durable remissions. However, lupus presents unique challenges: its autoimmune attacks are broader and less predictable than cancer’s targeted cell destruction. A 2024 study in Nature Medicine tested a similar therapy in mice and found it reduced lupus symptoms, but human trials had not previously shown remission.

The UK’s trial stands out for its use of autologous (patient-derived) cells rather than donor-derived CAR T-cells, which have been explored in earlier lupus research but carry higher risks of graft-versus-host disease. "The autologous approach is safer and more personalized," said Dr. Thomas, noting that the trial’s participants had all failed at least three prior treatments.

What are the next steps for approval and access?
The NHS has not yet approved the therapy for routine use, pending further trials. Researchers plan to expand the study to 50 patients across three UK hospitals by late 2027, with results expected in 2028. Regulatory hurdles remain significant: the U.S. Food and Drug Administration has not yet reviewed CAR T-cell therapies for lupus, though the therapy’s manufacturer, Kite Pharma (a Gilead company), has submitted preliminary data to the FDA.

Cost is another barrier. A single CAR T-cell treatment for cancer costs up to $475,000 in the U.S., and lupus therapies could be similarly priced. The NHS has not disclosed budgeting for the trial, but Sir Johnson told The Guardian that "if the data holds, we’ll work with manufacturers to ensure equitable access."

What risks and uncertainties remain?
While the early results are promising, experts caution against overestimating the therapy’s potential. "Remission in a small trial doesn’t equal a cure," said Dr. Richard Furie, chief of rheumatology at Northwell Health in New York, who was not involved in the study. "We need to see how long these remissions last and whether the therapy works in more diverse patient populations."

Side effects, though manageable in the trial, could include infections or secondary cancers—a risk seen in long-term CAR T-cell patients. The therapy also requires specialized facilities, limiting immediate global access. "This is a proof of concept," said Dr. Thomas. "The real work is scaling it up safely."

How are patients reacting?
One trial participant, 34-year-old Sarah Mitchell of Rhyl, Wales, told Upday News she had been bedridden for five years before the treatment. "I went from not being able to walk to skiing last winter," she said. "It’s not just about living—it’s about living." Mitchell, who had previously suffered kidney damage from lupus, now has normal kidney function and no longer takes steroids.

The emotional impact extends beyond physical health. "For years, doctors told us lupus was incurable," said Mitchell. "Now, we’re not just surviving—we’re thriving."

Key questions about the therapy’s future

1. Will the FDA approve it for lupus?
   The FDA has not yet indicated a timeline, but Kite Pharma’s submission of preliminary data suggests accelerated review is possible. Approval would likely hinge on the 2028 trial results.

2. Could this therapy work for other autoimmune diseases?
   Early lab research suggests CAR T-cell approaches may help rheumatoid arthritis and multiple sclerosis, but human trials are years away.

3. How will cost and access be managed?
   The NHS has not disclosed pricing, but given the therapy’s complexity, it may require new funding models or manufacturer discounts to ensure affordability.

4. Are there alternatives on the horizon?
   Other experimental lupus treatments, including B-cell depletion therapies and oral JAK inhibitors, are in late-stage trials, but none have shown remission rates comparable to CAR T-cells.

Bottom line
For the first time, a treatment has induced remission in severe lupus patients, offering hope to those who have exhausted all other options. While challenges remain—including long-term safety, cost, and regulatory approval—the UK trial represents a landmark shift in how lupus is treated. "This isn’t just a medical breakthrough," said Professor Johnson. "It’s a reminder that even the most stubborn diseases can be tackled with the right science and persistence."